Cinctive Capital Management LP Invests $2.25 Million in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Cinctive Capital Management LP acquired a new stake in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 92,628 shares of the company’s stock, valued at approximately $2,246,000.

A number of other hedge funds have also recently bought and sold shares of the company. Bank of America Corp DE boosted its position in Centessa Pharmaceuticals by 307.2% during the third quarter. Bank of America Corp DE now owns 553,007 shares of the company’s stock worth $13,410,000 after acquiring an additional 417,209 shares during the last quarter. Ameriprise Financial Inc. acquired a new position in Centessa Pharmaceuticals in the 3rd quarter valued at $2,619,000. Schonfeld Strategic Advisors LLC raised its holdings in Centessa Pharmaceuticals by 46.2% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 172,696 shares of the company’s stock valued at $4,188,000 after acquiring an additional 54,533 shares during the last quarter. Avoro Capital Advisors LLC lifted its stake in shares of Centessa Pharmaceuticals by 116.2% during the 3rd quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock worth $262,096,000 after purchasing an additional 5,808,080 shares during the period. Finally, Franklin Resources Inc. boosted its holdings in shares of Centessa Pharmaceuticals by 0.6% during the third quarter. Franklin Resources Inc. now owns 2,558,414 shares of the company’s stock worth $62,042,000 after purchasing an additional 14,875 shares during the last quarter. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Stock Up 7.4%

CNTA opened at $28.29 on Tuesday. Centessa Pharmaceuticals PLC Sponsored ADR has a 1 year low of $9.60 and a 1 year high of $30.58. The firm has a 50 day moving average price of $24.80 and a 200 day moving average price of $24.43. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56. The company has a market cap of $4.13 billion, a PE ratio of -15.46 and a beta of 1.54.

Insiders Place Their Bets

In related news, insider Gregory M. Weinhoff sold 73,196 shares of Centessa Pharmaceuticals stock in a transaction on Friday, March 13th. The shares were sold at an average price of $26.33, for a total transaction of $1,927,250.68. Following the transaction, the insider owned 65,925 shares in the company, valued at approximately $1,735,805.25. The trade was a 52.61% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Karen M. Anderson sold 120,029 shares of Centessa Pharmaceuticals stock in a transaction on Friday, March 13th. The shares were sold at an average price of $26.25, for a total transaction of $3,150,761.25. Following the transaction, the insider owned 62,085 shares in the company, valued at $1,629,731.25. The trade was a 65.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 233,186 shares of company stock worth $6,082,890 over the last ninety days. 7.09% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on CNTA shares. Oppenheimer lifted their price objective on Centessa Pharmaceuticals from $40.00 to $62.00 and gave the company an “outperform” rating in a research report on Wednesday, December 10th. Chardan Capital reiterated a “buy” rating and set a $30.00 target price on shares of Centessa Pharmaceuticals in a research report on Friday, January 2nd. Piper Sandler reissued an “overweight” rating on shares of Centessa Pharmaceuticals in a research note on Friday, January 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 21st. Finally, Truist Financial increased their price objective on shares of Centessa Pharmaceuticals from $33.00 to $38.00 and gave the stock a “buy” rating in a report on Thursday, January 29th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $39.80.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.